Short Answer

Both the model and the market expect Erica Schwartz to be confirmed as CDC director before August 1, 2026, with no compelling evidence of mispricing.

1. Executive Verdict

  • Financial interests and vaccine stance create significant confirmation objections.
  • Anticipated 2026 legislative backlog suggests a protracted confirmation process.
  • Confirmation is likely delayed past mid-2026 due to legislative backlog.
  • American Public Health Association actively supports Schwartz for CDC Director.
  • Market movement saw an 8 percentage point increase on April 17, 2026.

Who Wins and Why

Outcome Market Model Why
Before Jun 1, 2026 11.0% 7.6% Market higher by 3.4pp
Before Jul 1, 2026 35.0% 26.1% Market higher by 8.9pp
Before Aug 1, 2026 60.0% 50.2% Market higher by 9.8pp
Before Jan 1, 2027 0.0% 50.2% Model higher by 50.2pp

2. Market Behavior & Price Dynamics

Historical Price (Probability)

Outcome probability
Date
This market, which asks when Erica Schwartz will be confirmed as CDC director, has exhibited a sideways trend within a narrow range. The price opened at a 6.0% probability and is currently trading at 11.0%. The market has remained bounded between a low of 5.0% and a high of 12.0% throughout its history. The most significant price movement was a jump from 6.0% to 11.0% around April 29, 2026. Without any specific news or context provided, the direct cause for this upward shift is not apparent from the available information.
The total trading volume is very low at 95 contracts, and the sample data points show zero volume on several days, indicating thin and infrequent trading activity. This low volume suggests a lack of strong market conviction and means that even small trades can cause notable price swings. The price floor around 5.0-6.0% has acted as a support level, while the 12.0% mark has served as resistance.
Overall, the market sentiment is deeply skeptical about Schwartz's confirmation within the defined period. Despite the price nearly doubling from its opening, the probability has never exceeded 12.0%. The current price of 11.0% implies that traders see this outcome as highly unlikely, reflecting a strong consensus against the event occurring.

3. Significant Price Movements

Notable price changes detected in the chart, along with research into what caused each movement.

📈 April 17, 2026: 8.0pp spike

Price increased from 36.0% to 44.0%

Outcome: Before Aug 1, 2026

What happened: No supporting research available for this anomaly.

4. Market Data

View on Kalshi →

Contract Snapshot

The market resolves to "Yes" if Erica Schwartz is confirmed by the U.S. Senate as CDC director before August 1, 2026. This requires a successful Senate confirmation vote receiving the constitutionally required majority for the specified position; nominations without Senate action, committee approval, recess or acting appointments, withdrawn nominations, failed votes, or confirmation to a different position do not count. Otherwise, the market resolves to "No" and will close by July 31, 2026, at 11:59 PM EDT, with a projected payout 30 minutes after closing.

Available Contracts

Market options and current pricing

Outcome bucket Yes (price) No (price) Last trade probability
Before Jun 1, 2026 $0.12 $0.95 11%
Before Jul 1, 2026 $0.33 $0.73 35%
Before Aug 1, 2026 $0.61 $0.40 60%
Before Jan 1, 2027 $0.80 $0.23 0%

Market Discussion

Limited public discussion available for this market.

5. What are Senators' Stances on Erica Schwartz's CDC Nomination?

Nominee for CDC DirectorErica Schwartz [^]
Past RoleEx-deputy surgeon general [^]
Confirmation CommitteeSenate Committee on Health, Education, Labor, and Pensions (HELP) [^]
Erica Schwartz has been nominated to lead the CDC. Donald Trump has nominated Erica Schwartz to serve as the next director of the Centers for Disease Control and Prevention (CDC), bringing her background as an ex-deputy surgeon general to the role [^]. The confirmation process for this position falls under the purview of the Senate Committee on Health, Education, Labor, and Pensions (HELP) [^]. Both the HELP Committee and the Senate Appropriations Committee are expected to see new members following a reshuffling slated for January 2025 [^].
Specific public stances from key moderate senators are not available. While Erica Schwartz's nomination has garnered attention, with discussions surfacing about the potential for the new CDC chief to act independently on vaccines [^] and comparisons drawn to past CDC directors [^], the provided web research does not offer specific public stances from Senators Susan Collins, Lisa Murkowski, or Jon Tester concerning Schwartz's past policy decisions. These senators are often regarded as key moderate swing votes in the Senate, but their individual positions on Schwartz's nomination or her previous policy work are not detailed in the available sources. The confirmation process will involve scrutiny of her background and potential policy directions by the HELP Committee [^].

6. Who Supports or Opposes Erica Schwartz for CDC Director?

APHA StanceActively supporting Erica Schwartz for CDC Director [^]
The Iowa Standard StancePublished article opposing Schwartz leading the CDC [^]
Other Explicit Support/OppositionNone explicitly named in provided sources [^]
The American Public Health Association actively supports Erica Schwartz for CDC Director. This significant public health advocacy group has publicly expressed its support for Erica Schwartz's potential nomination as the CDC Director. The American Public Health Association (APHA) issued a news release endorsing Schwartz, stating that she possesses the necessary medical background and public health knowledge crucial for leading the CDC [^]. This demonstrates a key public health organization actively advocating for her confirmation.
The Iowa Standard online publication opposes Schwartz's CDC nomination. Conversely, the online publication The Iowa Standard has taken a stance against Schwartz's potential leadership of the CDC. They published an article titled "CDC Nominee Dr. Erica Schwartz Should Not Lead the CDC," detailing their opposition to her nomination [^]. The provided research does not explicitly name any other specific public health organizations, advocacy groups, or former senior officials as actively lobbying for or preparing opposition to Erica Schwartz.

7. What Objections Could Affect Erica Schwartz's CDC Nomination?

Current RoleDirector for Aveanna Healthcare Holdings Inc. (AVAH) since July 2021 [^]
Financial InterestsStock ownership in Aveanna Healthcare Holdings Inc. [^]
Controversial StancePublic record of supporting vaccine mandates [^]
Erica Schwartz's post-government employment reveals potential financial conflicts of interest. Since July 2021, Schwartz has served as a Director for Aveanna Healthcare Holdings Inc. (AVAH), a for-profit healthcare company [^]. Opposition senators could highlight this position, arguing that decisions made by a CDC director significantly influence the healthcare industry. Her financial interests, including ownership of shares in Aveanna Healthcare Holdings Inc., are publicly available through SEC filings [^].
Her public record of supporting vaccine mandates could prompt senatorial scrutiny. Schwartz has a documented history of advocating for vaccine mandates, a stance that has led some to label her the "Queen of Mandating Vaccines" [^]. This position is controversial among vaccine skeptics and certain political constituencies. Opposition senators might utilize her pro-mandate history to question her suitability for leading the CDC, especially if their constituents or political base oppose such mandates [^].

8. Who Was the White House's Nominated Candidate for CDC Director?

Nominated Candidate for CDC DirectorErica Schwartz (former Deputy Surgeon General) [^]
CDC Leadership Changes (pre-nomination year)Four [^]
Other Actively Promoted CandidatesNone identified in research [^]
Erica Schwartz emerged as the leading candidate for CDC Director under President Trump. The former Deputy Surgeon General was subsequently nominated by the White House to lead the Centers for Disease Control and Prevention (CDC) [^]. Her nomination followed a period of considerable instability at the agency, which had experienced four leadership changes within the year [^].
No other CDC Director candidates were actively promoted by influential groups. The research did not identify any other individuals being actively floated or promoted for the CDC Director position by influential think tanks or members of the Senate HELP Committee. Consequently, a comparative analysis of bipartisan support against Schwartz could not be performed based on the available information. While Senator Kennedy publicly stated the new CDC director would be allowed to make vaccine decisions, he was not mentioned as promoting alternative candidates [^].

9. When Will Erica Schwartz's CDC Director Confirmation Vote Happen?

Nominee and PositionErica Schwartz, CDC Director [^]
Earliest Floor Vote WindowJanuary or February 2026 [^]
Potential Confirmation DelayPast mid-2026 due to FY2026 appropriations [^]
Donald Trump nominated Erica Schwartz to serve as CDC director, a sub-cabinet position [^] . The confirmation process for such a role typically involves a committee hearing and vote, followed by placement on the Executive Calendar and a simple majority vote on the Senate floor [^]. If her nomination successfully clears committee by late 2025 or very early 2026, the earliest procedural window for a Senate floor vote in 2026 could emerge in January or February. This timing aligns with the Senate's tentative schedule, which indicates sessions commencing early in the year [^]. Active legislative proceedings noted for April 22, 2026, also present another potential opportunity for a vote [^].
However, must-pass legislation might delay Schwartz's confirmation past mid-2026 due to an anticipated significant legislative backlog. The primary "must-pass" legislation expected to consume substantial Senate floor time is the FY2026 appropriations process [^]. The Senate's adopted FY2026 Budget Resolution specifically identifies budget and appropriations bills as a central focus for 2026 [^]. Such legislation is often contentious and can dominate the legislative agenda, potentially pushing confirmation votes for sub-cabinet positions well into the latter half of 2026 if negotiations become prolonged [^].

10. What Could Change the Odds

Key Catalysts

Catalyst analysis unavailable.

Key Dates & Catalysts

  • Expiration: June 08, 2026
  • Closes: January 01, 2027

11. Decision-Flipping Events

  • Trigger: Catalyst analysis unavailable.

13. Historical Resolutions

No historical resolution data available for this series.